Navigation Links
Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
Date:8/14/2012

d macrophages in atherosclerotic plaques. Treatment with anti-microRNA-33 in an atherosclerotic mouse model led to reduction in arterial plaque size by 35% (Rayner et al., J Clin Invest. 2011) and treatment in non-human primates increased circulating levels of HDL-C by 50%. By enhancing RCT, anti-miR-33 differs from other emerging therapeutic strategies that focus only on raising HDL-C in circulation.

About microRNAs

The discovery of microRNAs in humans during the last decade is one of the most exciting scientific breakthroughs in recent history.  microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 500 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs.  microRNA expression, or function, has been shown to be significantly altered or dysregulated in many disease states, including oncology, fibrosis and metabolic diseases. In preclinical studies, Regulus has demonstrated that modulating microRNAs can effectively regulate disease pathways and produce therapeutically beneficial effects.

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is using a mature therapeutic platform based on technology that has been developed over 20 years. The company works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS). Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strateg
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nile Therapeutics Reports 2012 Second Quarter Financial Results
2. Zenobia Therapeutics Announce A Partnership With The Alzheimers Drug Discovery Foundation
3. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
4. Echo Therapeutics Announces Second Quarter 2012 Financial Results
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
6. Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences
7. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
8. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
9. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
10. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
11. Silence Therapeutics - Admission of Shares and Board Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets ... Target High Unmet Need in Newly ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
(Date:8/28/2014)... SAN DIEGO , Aug. 28, 2014 ... drug development company that merged with MabVax Therapeutics, ... has made significant progress related to the development ... fully-human antibody was recovered using the Company,s internally ... demonstrate the potential for multiple antibody based therapeutic ...
(Date:8/28/2014)... , Aug. 28, 2014 Amgen (NASDAQ: ... Biologics License Application (BLA) to the U.S. Food and ... treatment of high cholesterol. Evolocumab is an investigational fully ... 9 (PCSK9), a protein that reduces the liver,s ability ... from the blood. 1 ­ ...
Breaking Medicine Technology:Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... largest Phase 3 study conducted in MDS - Vidaza therapy confers ... survival advantage compared to conventional care regimens, - Two year overall survival ... ... Colo., Jan. 14 Pharmion Corporation,(Nasdaq: PHRM ) today announced the ...
... CEL-SCI Corporation,(Amex: CVM ) reports financial results ... reports a net operating loss for fiscal year 2007 ... fiscal year 2006. The loss per,share for fiscal year ... The cash from operating activities used during the ...
Cached Medicine Technology:Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 2Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 3Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 5Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 6Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 7CEL-SCI Corporation Announces 2007 Financial Results 2CEL-SCI Corporation Announces 2007 Financial Results 3
(Date:8/28/2014)... 29, 2014 The Global and China ... the current state of the Oscilloscope industry in Global ... of the industry, including definitions, applications and industry chain ... are provided with a focus on history, developments, trends ... the international and Chinese situation is also offered. , ...
(Date:8/28/2014)... Top10BestSEOHosting.com has recently compared many professional web ... Bluehost are the best hosting suppliers in 2014. ... in the hosting industry for more than 13 ... GB connections to ensure that there would be ... The great thing is that all hosted websites ...
(Date:8/28/2014)... Lake Worth, FL (PRWEB) August 28, 2014 ... promote National Recovery Month throughout September. This month ... of addiction treatment and mental health services. Along ... Millennium Treatment Group is helping to spread the ... Month began in 1989, honoring the work of ...
(Date:8/28/2014)... TN (PRWEB) August 28, 2014 American ... insurance industry on the Internet will now have a ... Pros company. In one click this year, some of ... at http://quotespros.com/life-insurance.html . , The promoted plans ... Quotes Pros finder tool represent popular policies. The term, ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ABC television ... the 49th MDA Show of Strength Telethon airing Sunday, ... country to help raise funds and awareness to help ... affected by muscle disease. , Viewers tuning into the ... enjoy heart-felt appeals and introductions from some of the ...
Breaking Medicine News(10 mins):Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 2Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 3Health News:Best Suppliers of Affordable Hosting Products Introduced by Top10BestSEOHosting.com 2Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4
... Neuisys Imaging System,Solutions, LLC announced today that the U.S. ... the NeuViz 16 Multi-Slice Computed,Tomography (CT) System. The NeuViz ... venture between Royal Philips Electronics of the Netherlands,and Neusoft ... NeuViz 16 is a state-of-the-art CT system that provides ...
... hypertension during pregnancy, Marshal D. Lindheimer, MD, professor emeritus ... Medicine and in the Committee on Clinical Pharmacology and ... 2009 Joseph Bolivar DeLee Humanitarian Award from the Board ... University of Chicago Medical Center. , The ...
... Accounting Related to Two Transactions , PHOENIX, Feb. 23 ... in stabilized rice bran (SRB) nutrient research and technology, ... recommendations of the Audit Committee of its Board of ... fiscal year ended December 31, 2007. This includes the ...
... 23 HealthyPlace.com , which provides the most extensive ... the internet, unveils several important new features for those ... features HealthyPlace Mediminder , a free medication reminder ... them to take their medication or refill their prescription. ...
... Fiber Bring Great Taste and Digestive Health Benefits to ... Company, Inc., announced today that it will expand the ... probiotic portfolio. Both cultured fresh dairy products, Activia Dairy ... the same scientifically proven benefits of all Activia products, ...
... say yes, but American experts aren,t so sure , , ... Taiwan links aggression in teens to heavy Internet use, ... , The research, based on questionnaires about Internet ... percent of the boys and 13 percent of the girls ...
Cached Medicine News:Health News:Neuisys Announces FDA Clearance of NeuViz 16 Multi-Slice CT System 2Health News:2009 DeLee Humanitarian Award goes to Marshall Lindheimer, M.D., of the University of Chicago 2Health News:2009 DeLee Humanitarian Award goes to Marshall Lindheimer, M.D., of the University of Chicago 3Health News:NutraCea to Restate Financial Statements for 2007 and 2008 2Health News:NutraCea to Restate Financial Statements for 2007 and 2008 3Health News:NutraCea to Restate Financial Statements for 2007 and 2008 4Health News:NutraCea to Restate Financial Statements for 2007 and 2008 5Health News:HealthyPlace.com, the Largest Consumer Mental Health Site, Re-Launches With Important New Features for the More Than 30 Million People Who Suffer from Anxiety, Depression and Bipolar Disorder 2Health News:HealthyPlace.com, the Largest Consumer Mental Health Site, Re-Launches With Important New Features for the More Than 30 Million People Who Suffer from Anxiety, Depression and Bipolar Disorder 3Health News:Dannon(TM) Expands Probiotic Portfolio with New Activia(TM) Extensions 2Health News:Dannon(TM) Expands Probiotic Portfolio with New Activia(TM) Extensions 3Health News:Are Internet-Addicted Kids More Violent? 2
This 100 µL is the equivalent to the "Universal Blue" tips and fits virtually every manufacturer's 1000 µL Pipettor....
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
Volume range 0.2-10 l. Designed for pipetting micro-sized drops. Ideal for use with micro volume Finnpipettes....
Conducting disposable tips....
Medicine Products: